SCM
PLX icon

Stevens Capital Management’s Protalix BioTherapeutics PLX Stock Holding History

Stevens Capital Management’s Portfolio PLX Stock Details PLX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q4 		– Sell
-2,237
Closed -$54K – 1172
2014
Q3 		$54K Buy
+2,237
New +$64.5K ﹤0.01% 957

Other funds holding PLX

Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
BA
BlackRock Advisors Wilmington, Delaware $98.8B AUM 15.8% 1-Year Est. Return
DCM
DAFNA Capital Management Los Angeles, California $440M AUM 109.12% 1-Year Est. Return
MMH
Menora Mivtachim Holdings Ramat Gan, Israel $21.1B AUM 40.03% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
MTWSIF
Mivtachim The Workers Social Insurance Fund Tel Aviv, Israel $789M AUM 73.25% 1-Year Est. Return
California Public Employees Retirement System
California Public Employees Retirement System Sacramento, California $162B AUM 25.78% 1-Year Est. Return

Stevens Capital Management's PLX Position: Q4 2014 in Review

Stevens Capital Management sold out of Protalix BioTherapeutics (PLX) in Q4 2014, closing a stake of 2,237 shares — an estimated $54K sold.

Stevens Capital Management first reported a position in PLX in Q3 2014 and held it in 1 quarter. The position peaked at $54K in Q3 2014. 44 funds tracked by Wall St. Rank hold PLX as of Q4 2014.

  • Stevens Capital Management reported no remaining Protalix BioTherapeutics position as of Q4 2014 after selling out during the quarter.
  • Stevens Capital Management sold 2,237 Protalix BioTherapeutics shares in Q4 2014, an estimated $54K.
  • Stevens Capital Management first reported a position in Protalix BioTherapeutics in Q3 2014 and held it in 1 quarter.
  • Stevens Capital Management's Protalix BioTherapeutics position peaked at $54K in Q3 2014.
  • 44 funds tracked by Wall St. Rank held Protalix BioTherapeutics as of Q4 2014.

Based on Stevens Capital Management's 13F filing for Q4 2014, filed 10 Feb 2015.